Compare Novavax Inc (NVAX) vs Vistra Corp (VST) Price & Performance

Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.

Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.

Vistra Corp (VST) trades at $157.99, up 1.64% with strong institutional support and bullish technical signals. The stock shows robust fundamentals with 74.92% ROE and 11.52% net margin, though recent earnings were mixed with Q1 2026 beating expectations but Q3 and Q4 2025 missing. Analyst consensus remains overwhelmingly positive with 91% buy ratings and a $253 price target, representing 60% upside potential. Recent news highlights Vistra's positioning in the AI power infrastructure boom and long-term power purchase agreements with major tech companies.

Vistra presents significant growth potential driven by AI infrastructure demand and nuclear energy expansion, but faces risks from power price volatility and high debt levels. The company's diversified utility operations and strategic PPAs provide revenue stability, while technical indicators suggest continued upward momentum with key resistance at $159-$162. Investors should weigh the strong analyst support against execution risks in capital-intensive energy projects.